Background: The safety and efficacy of high-dose sublingual-swallow immunotherapy (SLIT) has been established in pollen rhinoconjunctivitis. This treatment has now been evaluated using an ultra-rush incremental dose regimen with a Juniperus ashei allergen extract in patients allergic to Cupressus sempervirens and Cupressus arizonica. Methods: Patients received either placebo or SLIT. Evaluation of safety was based on the frequency of adverse events during the incremental dose period (half a day) and during maintenance therapy (4 months). Evaluation of efficacy was based on symptom and medication scores at the pollen peak. Results: Seventy of the 76 patients included completed the study. There were no drop-outs during the rush procedure. One patient in the active group dropped out during the maintenance therapy due to adverse events: gastric pain and vomiting. There was also 1 drop-out in the placebo group due to pregnancy. Adverse events were infrequent, local and mild. Symptom scores for rhinitis and conjunctivitis were not statistically different between groups, but there was a marked and significant (p < 0.03) decrease of the medication score (about 50%) and nasal steroid consumption (about 75%) in the active treatment group. An increase from baseline of serum IgE and IgG4 J. ashei-specific antibodies was only observed in actively treated patients (p < 0.04 and p < 0.01, respectively). Conclusions: The tolerability and safety of high-dose ultra-rush SLIT were comparable to those reported in previous SLIT studies. SLIT with J. ashei extract, due to its high Jun a 1 content, significantly reduced nasal steroid consumption in patients allergic to European cypress.

Keywords:
Rush, Immunotherapy, sublingual, Rhinoconjunctivitis, Cypress, Juniperus ashei
1.
Birnbaum J, Ramadour M, Magnan A, Vervloet D: Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Clin Exp Allergy 2003;33:58–64.
2.
Bousquet J, Hejjaoui A, Skassa-Brociek W, Guérin B, Maasch HJ, Dhivert H, Michel FB: Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987;80:591–598.
3.
Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989;83:797–802.
4.
Harvey SM, Laurie S, Hilton K, Khan DA: Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol 2004;92:414–419.
5.
Klimek L, Wolf H, Mewes T, Dormann D, Reske-Kunz AB, Schnitker J, Mann W: The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 1999;103:47–53.
6.
Tabar AI, Muro MD, Garcia BE, Alvarez MJ, Acero S, Rico P, Olaguibel JM: Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy. Invest Allergol Clin Immunol 1999;9:155–164.
7.
Parmiani S, Tavora LF, Moreno C, Guardia P, Rico P: Clustered schedules in allergen-specific immunotherapy. Allergol Immunopathol 2002;30:283–291.
8.
Wilson DR, Torres Lima M, Durham SR: Sublingual Immunotherapy for Allergic Rhinitis (Cochrane Review). Oxford, The Cochrane Library, 2003, issue 2 (update software).
9.
Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling H-J: Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:45–53.
10.
Feliziani V, Lattuada G, Parmiani S, Dall’Aglio P: Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol 1995;23:224–230.
11.
Purello D’Ambrosio F, Ricciardi L, Isola S, Puccinelli P, Musarra A: Rush sublingual immunotherapy in Parietaria allergic patients. Allergol Immunopathol 1996;24:146–151.
12.
Voltolini S, Modena P, Minale P, Bignardi D, Troise C, Puccinelli P, Parmiani S: Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollen (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol 2001;29:103–110.
13.
Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P, Parmiani S, Canonica GW: Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999;104:964–968.
14.
Vervloet D, Birnbaum J, Laurent P, Hugues B, Fardeau MF, Massabié-Bouchat YP, Aferiat-Derome A, Vatrinet C, André C: Safety and clinical efficacy of rush sublingual cypress immunotherapy: preliminary results. Allergy 2002;57(suppl 73):70.
15.
Tripodi S, Di Rienzo Businco A, Benincori N, Scala G, Pingitore G: Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol 2006;139:149–152.
16.
Gammeri E, Arena A, D’Anneo R, La Grutta S: Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol 2005;33:221–223.
17.
Rossi RE, Monasterolo G, Coco G, Operti D: Possible relationship between systemic side-effects and sensitization to r Par j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis. Int Arch Allergy Immunol 2005;138:105–110.
18.
Hrabina M, Dumur JP, Sicard H, Viatte A, André C: Diagnosis of cypress pollen allergy: in vivo and in vitro standardization of a Juniperus ashei pollen extract. Allergy 2003;58:808–813.
19.
Arilla MC, Ibarrola I, Martinez A, Asturias JA: Quantification assay for the major allergen of Cupressus sempervirens pollen, Cup s 1, by sandwich ELISA. Allergol Immunopathol 2004;32:319–325.
20.
Mari A, Di Felice G, Afferni C, Barletta B, Tinghino R, Sallustro F, Pini C: Assessment of skin prick test and serum specific IgE detection in the diagnosis of Cupressaceae pollinosis. J Allergy Clin Immunol 1996;98:21–31.
21.
Di Felice G, Barletta B, Tinghino R, Pini C: Cupressaceae pollinosis: identification, purification and cloning of relevant allergens. Int Arch Allergy Immunol 2001;125:280–289.
22.
Malling H-J, Weeke B: Immunotherapy (position paper). EAACI Immunotherapy Subcommittee. Allergy 1993;48:3–35.
23.
Tari MG, Mancino M, Monti G: Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol 1990;18:277–284.
24.
André C, Vatrinet C, Galvain S, Carat F, Sicard H: Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121:2229–2234.
25.
Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheinmann P, Rufin P, Basset D, Fadel R, André C: Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 2002;129:248–253.
26.
Coopman SA, Johnson RA, Platt R, Stern RS: Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670–1674.
27.
Kletzel M, Beck S, Elser J, Shock N, Burks W: Trimethoprim-sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions. Am J Dis Child 1991;145:1428–1429.
28.
Gluckstein D, Ruskin J: Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995;20:849–853.
29.
Kalanadhabhatta V, Muppidi D, Sahni H, Robles H, Kramer M: Successful oral desensitization to trimethoprim-sulfamethoxazole in acquired human immunodeficiency virus-infected syndrome. Ann Allergy Asthma Immunol 1996;77:394–400.
30.
Miller FF, Smith RE, Lanson WJ: Repository emulsion therapy for mountain cedar pollinosis: a double-blind study. J Allergy 1964;35:7–11.
31.
Pence HL, Mitchell DQ, Greely RL et al: Immunotherapy for mountain cedar pollinosis. A double-blind study. J Allergy Clin Immunol 1976;58:39–50.
32.
Fling JA, Ruff ME, Parker WA, et al: Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol 1989;83:101–109.
33.
Parker W, Whisman B, Apaleski S, et al: The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol 1989;84:667–677.
34.
Ariano R, Panzani RC, Augeri G: Double-blind, placebo-controlled specific immunotherapy with mixed Cupressaceae taxodiaceae pollens in respiratory allergy to Cupressus sempervirens. Allergol Immunopathol 1997;25:23–29.
35.
Ito Y, Takahashi Y, Fujita T, et al: Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollinisation. Auris Nasus Larynx 1977;24:163–170.
36.
Clavel R, Bousquet J, André C: Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998;53:493–498.
37.
Bousquet J, van Cauwenberge P, Khaltaev N; ARIA Workshop Report: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:1–334.
38.
André C, Perrin-Fayolle M, Grosclaude M, Couturier P, Basset D, Cornillon J, Piperno D, Girodet B, Sanchez R, Vallon C, Bellier P, Nasr M: A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003;131:118.
39.
André C, Dumur JP, Hrabina M, Lefebvre E, Sicard H: Juniperus ashei: le golden standard des cupressacées. Allergie Immunol 2000;32:104–106.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.